This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Meridian Bioscience Management

Management criteria checks 2/4

Key information

Jack Kenny

Chief executive officer

US$4.6m

Total compensation

CEO salary percentage	15.4%
CEO tenure	5.3yrs
CEO ownership	0.3%
Management average tenure	3.6yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jack Kenny's remuneration changed compared to Meridian Bioscience's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	US$5m	US$710k	US$42m
Jun 30 2022	n/a	n/a	US$43m
Mar 31 2022	n/a	n/a	US$62m
Dec 31 2021	n/a	n/a	US$60m
Sep 30 2021	US$3m	US$690k	US$71m
Jun 30 2021	n/a	n/a	US$71m
Mar 31 2021	n/a	n/a	US$87m
Dec 31 2020	n/a	n/a	US$70m
Sep 30 2020	US$3m	US$670k	US$46m
Jun 30 2020	n/a	n/a	US$44m
Mar 31 2020	n/a	n/a	US$21m
Dec 31 2019	n/a	n/a	US$19m
Sep 30 2019	US$1m	US$650k	US$24m
Jun 30 2019	n/a	n/a	US$26m
Mar 31 2019	n/a	n/a	US$27m
Dec 31 2018	n/a	n/a	US$26m
Sep 30 2018	US$2m	US$542k	US$24m

Compensation vs Market: Jack's total compensation ($USD4.60M) is above average for companies of similar size in the UK market ($USD2.11M).

Compensation vs Earnings: Jack's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Jack Kenny (53 yo)

5.3yrs

Tenure

US$4,598,825

Compensation

Mr. John P. Kenny, also known as Jack, has been the Chief Executive Officer of Meridian Bioscience, Inc. since October 9, 2017. Mr. Kenny serves as President of Meridian Bioscience, Inc. and served as its...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Kenny	President	5.3yrs	US$4.60m	0.28% $ 4.2m
Andrew Kitzmiller	Executive VP & CFO	less than a year	US$1.03m	0.0092% $ 137.4k
Julie Smith	Senior VP	1.2yrs	US$786.42k	0.097% $ 1.5m
Lourdes Weltzien	Executive Vice President of Life Science Business Unit	9.4yrs	US$1.23m	0.13% $ 2.0m
Tony Serafini-Lamanna	Executive Vice President of Diagnostics	2.8yrs	US$1.20m	0.038% $ 567.0k
Jeff Pinkston	Director of Corporate Finance	no data	no data	no data
Charles Wood	Vice President of Corporate Strategy	3.1yrs	no data	no data
Emerson Moser	Senior VP & General Counsel	less than a year	no data	no data
Melissa McCarey	Vice President of Global Human Resources	4.8yrs	no data	no data
Susan Rolih	Consultant	4.3yrs	US$626.75k	no data
Melissa Lueke	Consultant	4.1yrs	US$432.97k	no data

3.6yrs

Average Tenure

57yo

Average Age

Experienced Management: 0K0K's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Kenny	President	6.1yrs	US$4.60m	0.28% $ 4.2m
John Rice	Independent Director	5.5yrs	US$176.25k	0.056% $ 833.6k
John McIlwraith	Chairman	7.5yrs	US$212.75k	0.043% $ 638.2k
James Anderson	Independent Director	13.6yrs	US$197.00k	0.069% $ 1.0m
Felicia Williams	Independent Director	4.4yrs	US$192.50k	0.017% $ 247.7k
Anthony Bihl	Independent Director	2.6yrs	US$189.63k	0.028% $ 422.8k
Dwight Ellingwood	Independent Director	8.6yrs	US$177.50k	0.033% $ 487.1k
Catherine Sazdanoff	Independent Director	7.5yrs	US$191.13k	0.031% $ 457.5k

6.8yrs

Average Tenure

66yo

Average Age

Experienced Board: 0K0K's board of directors are considered experienced (6.8 years average tenure).

This company listing is no longer active

Meridian Bioscience Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Insufficient new directors

Meridian Bioscience, Inc. Announces Board Changes

Recent updates

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Insufficient new directors

Full year 2022 earnings released: EPS: US$0.97 (vs US$1.65 in FY 2021)

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 profit in 3Q 2021)

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

Insufficient new directors

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix

Investor sentiment deteriorated over the past week

President recently sold US$250k worth of stock

Investor sentiment improved over the past week

Meridian Bioscience, Inc. Announces the Launch of New Air-Dryable Direct DNA qPCR Blood Mix

Meridian Bioscience Provides A Further Update on the Revogene® Sars-Cov-2 Eua Submission

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides an Update on the Revogene SARS-CoV-2 EUA Submission

First quarter 2021 earnings released: EPS US$0.62 (vs US$0.066 in 1Q 2020)

Revenue beats expectations

Investor sentiment improved over the past week

Meridian Bioscience, Inc. Raises Consolidated Earnings Guidance for the Fiscal Year 2021

Meridian’s Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays

Meridian Bioscience, Inc. to Report Q1, 2021 Results on Feb 05, 2021

Meridian Bioscience, Inc., Annual General Meeting, Jan 27, 2021

Market pulls back on stock over the past week

Meridian Bioscience, Inc. Launches Its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

Independent Director recently bought US$88k worth of stock

Market pulls back on stock over the past week

Full year 2020 earnings released: EPS US$1.08

Revenue beats expectations

Meridian Bioscience, Inc. Launches Complete Solution Improving the Development of Cancer Diagnostic Tests

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure